{"nctId":"NCT05763875","briefTitle":"Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.","startDateStruct":{"date":"2023-03-15","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":350,"armGroups":[{"label":"Inclisiran","type":"EXPERIMENTAL","interventionNames":["Drug: Inclisiran","Drug: Matching Placebo for Ezetimibe"]},{"label":"Ezetimibe","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ezetimibe","Drug: Matching Placebo for Inclisiran"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo for Inclisiran","Drug: Matching Placebo for Ezetimibe"]}],"interventions":[{"name":"Inclisiran","otherNames":["KJX839"]},{"name":"Ezetimibe","otherNames":["Sandoz ezetimibe"]},{"name":"Matching Placebo for Inclisiran","otherNames":["Placebo s.c."]},{"name":"Matching Placebo for Ezetimibe","otherNames":["Placebo p.o."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria at screening:\n\n* informed consent signed prior to participation in study\n* fasting LDL-C of \\>= 100 mg/dL but \\< 190 mg/dL\n* fasting triglycerides \\<= 400 mg/dL\n* 10-year ASCVD risk score \\< 7.5%\n* not on any lipid-lowering therapy within 90 days of screening\n\nKey Exclusion Criteria:\n\n* history of ASCVD\n* diabetes mellitus or fasting plasma glucose of \\>= 7.0 mmol/L or HbA1c \\>= 6.5%\n* secondary hypercholesterolemia, e.g. hypothyroidism (TSH above upper limit of normal)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150","description":"Percentage change in LDL-C from Baseline (day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.54","spread":null},{"groupId":"OG001","value":"-11.17","spread":null},{"groupId":"OG002","value":"1.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.37","spread":null},{"groupId":"OG001","value":"-11.92","spread":null},{"groupId":"OG002","value":"-1.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in LDL-C From Baseline to Day 150","description":"Absolute change in LDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.86","spread":null},{"groupId":"OG001","value":"-17.55","spread":null},{"groupId":"OG002","value":"-1.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.57","spread":null},{"groupId":"OG001","value":"-18.52","spread":null},{"groupId":"OG002","value":"-1.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 150","description":"Percentage change in PCSK9 from Baseline (Day 1) to Day 150 , Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.12","spread":null},{"groupId":"OG001","value":"6.04","spread":null},{"groupId":"OG002","value":"7.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.31","spread":null},{"groupId":"OG001","value":"5.56","spread":null},{"groupId":"OG002","value":"8.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 150","description":"Percentage change in non-HDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.45","spread":null},{"groupId":"OG001","value":"-9.97","spread":null},{"groupId":"OG002","value":"1.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.82","spread":null},{"groupId":"OG001","value":"-10.84","spread":null},{"groupId":"OG002","value":"2.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Total Cholesterol (TC)/HDL-C Ratio From Baseline to Day 150","description":"Percentage change in total cholesterol/HDL-C ratio from Baseline (Day1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strate","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.54","spread":null},{"groupId":"OG001","value":"-6.70","spread":null},{"groupId":"OG002","value":"2.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.56","spread":null},{"groupId":"OG001","value":"-6.98","spread":null},{"groupId":"OG002","value":"2.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Apolipoprotein B (Apo B) From Baseline to Day 150","description":"Percentage change in Apo B from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.39","spread":null},{"groupId":"OG001","value":"-8.41","spread":null},{"groupId":"OG002","value":"-0.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.36","spread":null},{"groupId":"OG001","value":"-9.20","spread":null},{"groupId":"OG002","value":"-0.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Apo B/Apo A-1 Ratio From Baseline to Day 150","description":"Percentage change in Apo B/Apo A-1 ratio from baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.79","spread":null},{"groupId":"OG001","value":"-7.55","spread":null},{"groupId":"OG002","value":"-2.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.03","spread":null},{"groupId":"OG001","value":"-7.69","spread":null},{"groupId":"OG002","value":"-2.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Lipoprotein (a) [Lp(a)] From Baseline to Day 150","description":"Day 150 / Baseline ratio in Lp(a) in Inclisiran arm versus Ezetimibe and placebo.\n\nThere were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows:\n\n* Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen.\n* Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.690","spread":null},{"groupId":"OG001","value":"0.911","spread":null},{"groupId":"OG002","value":"0.923","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.687","spread":null},{"groupId":"OG001","value":"0.912","spread":null},{"groupId":"OG002","value":"0.922","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)","description":"Incidence of TEAEs (regardless of seriousness) and SAEs by treatment group, including changes in laboratory results qualifying and reported as AEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":174},"commonTop":["Nasopharyngitis","Urinary tract infection","COVID-19","Headache","Diarrhoea"]}}}